Histopathology reporting for personalised medicine: focus on clinical utility

被引:0
|
作者
Mason, Anna Elizabeth [1 ]
Varma, Murali [1 ]
机构
[1] Univ Hosp Wales, Dept Cellular Pathol, Cardiff, Wales
关键词
diagnosis; neoplasms; pathology; surgical; process assessment; health care; medical oncology;
D O I
10.1136/jclinpath-2022-208185
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histopathology guidelines generally focus on standardised collection of data items to facilitate completeness and reproducibility of histopathology reporting. A data item is categorised as either core (mandatory) or non-core (recommended but not mandatory), irrespective of the clinical scenario. However, a data item that is critical for patient management in one clinical setting may have little clinical significance in another setting. A diagnosis of limited extent Gleason score 3+3=6 prostate cancer is critical in a patient being investigated for raised serum prostate-specific antigen but would be clinically irrelevant in a repeat biopsy from a patient on an active surveillance protocol. We outline an alternative approach that is focused on the clinical utility of the data items and the requirements of personalised medicine. While all core data items are required to be reported, understanding how these parameters are used to guide patient management will enable pathologists to focus time and resources on the critical aspects of an individual case. Detailed immunohistochemical workup and obtaining a second opinion would not be necessary if resolution of the differential diagnosis is of limited clinical significance. We also highlight some challenges encountered when adopting this approach and suggest some solutions that could positively impact histopathology reporting and patient care.
引用
收藏
页码:525 / 528
页数:4
相关论文
共 50 条
  • [1] A Utility Tool for Personalised Medicine
    Gavankar, Chetana
    Phatak, Aditya
    Thakkar, Nikita
    Patel, Vaidehi
    Pragda, Bhoomi
    Lathkar, Rutuja
    PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON VISION, IMAGE AND SIGNAL PROCESSING (ICVISP 2018), 2018,
  • [2] Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine
    Drucker E.
    Krapfenbauer K.
    EPMA Journal, 2013, 4 (1):
  • [3] Forget personalised medicine and focus on abating disease activity
    Smolen, Josef S.
    Aletaha, Daniel
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (01) : 3 - 6
  • [4] Digital Health in Focus of Predictive, Preventive and Personalised Medicine
    Mszar, Reed
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 2021, 94 (01): : 193 - 194
  • [5] Applying personalised medicine in clinical practice
    Pirmohamed, Munir
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 : A4 - A4
  • [6] Personalized histopathology reporting for personalized medicine: a plea for improved communication
    Murali Varma
    Brett Delahunt
    W. Glenn McCluggage
    Varsha I. Shah
    Daniel M. Berney
    Virchows Archiv, 2020, 477 : 323 - 325
  • [7] Personalized histopathology reporting for personalized medicine: a plea for improved communication
    Varma, Murali
    Delahunt, Brett
    McCluggage, W. Glenn
    Shah, Varsha I.
    Berney, Daniel M.
    VIRCHOWS ARCHIV, 2020, 477 (02) : 323 - 325
  • [8] Clinical utility of histopathology data: urological cancers
    Varma, Murali
    Williamson, Sean
    JOURNAL OF CLINICAL PATHOLOGY, 2022, 75 (08) : 506 - 513
  • [9] How Personalised is Personalised Medicine?
    Riedler, Josef
    PADIATRIE UND PADOLOGIE, 2019, 54 (01): : 1 - 1
  • [10] Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
    Longhitano, Elisa
    Muscolino, Paola
    Lo Re, Claudia
    Ferrara, Serena Ausilia
    Cernaro, Valeria
    Gembillo, Guido
    Tessitore, Dalila
    Speranza, Desiree
    Figura, Francesco
    Santarpia, Mariacarmela
    Silvestris, Nicola
    Santoro, Domenico
    Franchina, Tindara
    CANCERS, 2023, 15 (06)